drugset / Trial / NCT04982276
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .
Timeline
- Start
- 2021-08-23
- Primary completion
- 2025-12-30
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Subject | pulocimab | Monoclonal antibody | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |